Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.

about

Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.

Item

http://www.wikidata.org/entity/Q53066540

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Bone marrow vascular endotheli ...... iffuse large B-cell lymphomas.

@en

Bone marrow vascular endotheli ...... iffuse large B-cell lymphomas.

@nl

type

Item

label

Bone marrow vascular endotheli ...... iffuse large B-cell lymphomas.

@en

Bone marrow vascular endotheli ...... iffuse large B-cell lymphomas.

@nl

prefLabel

Bone marrow vascular endotheli ...... iffuse large B-cell lymphomas.

@en

Bone marrow vascular endotheli ...... iffuse large B-cell lymphomas.

@nl

P1476

Bone marrow vascular endotheli ...... iffuse large B-cell lymphomas.

@en

P2093

Byung Soo Kim

http://www.w3.org/2001/XMLSchema#string

Chul Won Choi

http://www.w3.org/2001/XMLSchema#string

Dae Sik Kim

http://www.w3.org/2001/XMLSchema#string

Ga Won Gang

http://www.w3.org/2001/XMLSchema#string

Hwa Jung Sung

http://www.w3.org/2001/XMLSchema#string

Jung Sun Kim

http://www.w3.org/2001/XMLSchema#string

Se Ryun Lee

http://www.w3.org/2001/XMLSchema#string

Young Park

http://www.w3.org/2001/XMLSchema#string

P2860

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.

VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody.

Novel therapeutic agents for B-cell lymphoma: developing rational combinations.

Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer.

Expression and significance of vascular endothelial growth factor A and C in leukemia central nervous system metastasis.

Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients.

P304

914-920

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYV102

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26185139

http://www.w3.org/2001/XMLSchema#string